JMA Journal

Figure 1. Participants by (A) department and (B) facility (n = 1,701).

Figure 2. Level of AHA awareness (A) overall and (B) by department (responses to “Select one of the following options that apply to your own knowledge and understanding of ‘acquired hemophilia A’”) (n = 1,701).
AHA: acquired hemophilia A.

Figure 3. Experience examining patients with AHA (A) overall and (B) by department (responses to: “Have you ever examined patients with ‘acquired hemophilia A’?”) (n = 1,701).
AHA: acquired hemophilia A.

Figure 4. Experience examining patients who present with AHA symptoms (A) overall and (B) by department (responses to: “Select all that apply to your answers from the following symptoms if you have examined patients presenting with...”) (n = 1,701).
AHA: acquired hemophilia A.

Figure 5. Proportion of participants who suspected an acquired coagulopathy diagnosis based on the fictitious case (A) overall and (B) by department (responses to: fictitious case: “If you were to examine the following patient, which disease would you suspect? Select the level of suspicion for each disease”) and the proportion of participants who suspected an acquired coagulopathy diagnosis when provided with laboratory test results for the fictitious case (C) overall and (D) by department (responses to: fictitious case with clinical laboratory results [Supplementary Table 1]: “For the fictitious case in the previous question, if the following further test results are known, which disease would you suspect? Select the level of suspicion for each disease”) (n = 1,701).
AHA: acquired hemophilia A.

Figure 6. Diseases suspected by participants for the AHA fictional case (A) initially (responses to: fictitious case: “If you were to examine the following patient, which disease would you suspect? Select the level of suspicion for each disease”; 39 participants indicated they suspected or strongly suspected other diseases that were not listed) and (B) when provided with laboratory test results (responses to: fictitious case with clinical laboratory results [Supplementary Table 1]: “For the fictitious case in the previous question, if the following further test results are known, which disease would you suspect? Select the level of suspicion for each disease”; 34 participants indicated they suspected or strongly suspected other diseases that were not listed) (n = 1,701).
ADR: adverse drug reaction; AHA: acquired hemophilia A; DIC: disseminated intravascular coagulation; HSP: Henoch–Schönlein purpura; IgA: immunoglobin A; ITP: idiopathic thrombocytopenic purpura; TTP: thrombotic thrombocytopenic purpura.